Oramed submits request for new U.S. oral insulin trial; Analysts expect the inhalation market to reach $47M by 2017;

> Oramed ($ORMP) submitted a pre-IND meeting request to the FDA for a U.S. trial of its oral insulin capsule, ORMD-0901. Release

> Industry analysts concluded that inhalation drug delivery systems are gathering momentum with the development of faster acting and more effective products, with the global market expected to reach $47 billion by 2017. Release

> Catalent bought Chinese softgel firm Zhejiang Jiang Yuan Tang Biotechnology, building upon its existing softgel network in Asia Pacific, including facilities in Japan and Australia. More

> Bespak Europe won government funding to the tune of up to £1 million ($1.52 million) from the U.K.'s Department of Health to develop a new bolus drug delivery device entering Phase II. Article

> Oxford Pharmascience extended its collaboration with University College London to further develop its drug-delivery compounds, giving Oxford the option on over 53 compounds to commercialize with the university. Article

Suggested Articles

Armed with microrobots and magnetic fields, Pursue scientists are looking to the future of targeted drug delivery, starting with the colon.

Zosano will need to run additional studies and await an FDA inspection to address the agency's complete response letter on its migraine patch Qtrypta.

Nanoform Finland tapped Quotient Sciences to help run the first in-human trial of a drug developed using its 'nanoforming' technology later this year.